Literature DB >> 8328787

In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.

L A Collins1, G M Eliopoulos, C B Wennersten, M J Ferraro, R C Moellering.   

Abstract

In vitro activity of ramoplanin, a cyclic lipoglycopeptide, against 92 vancomycin-resistant gram-positive organisms was evaluated. Ramoplanin demonstrated potent activity against many highly vancomycin-resistant organisms including enterococci (MICs for 90% of strains tested of 0.5 micrograms/ml) and against Lactobacillus spp., Leuconostoc spp., and Pediococcus spp., all of which were inhibited at concentrations of < or = 0.25 micrograms/ml. This drug or a derivative compound merits further investigation as a potential therapeutic agent for infections due to vancomycin-resistant enterococci.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8328787      PMCID： PMC187967          DOI： 10.1128/AAC.37.6.1364

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Resistance of enterococci to glycopeptides.

Authors:  P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 3.  Infection due to Leuconostoc species: six cases and review.

Authors:  S Handwerger; H Horowitz; K Coburn; A Kolokathis; G P Wormser
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

4.  In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1989 May-Jun       Impact factor: 2.803

5.  In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin.

Authors:  N Yamane; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Jul-Aug       Impact factor: 2.803

6.  In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G J Malanoski; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Lactobacillus plantarum endocarditis in a patient with benign monoclonal gammopathy.

Authors:  J Struve; O Weiland; C E Nord
Journal:  J Infect       Date:  1988-09       Impact factor: 6.072

8.  Inhibition of peptidoglycan biosynthesis by ramoplanin.

Authors:  E A Somner; P E Reynolds
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

9.  Vancomycin-resistant Pediococcus acidilactici: nine cases of bacteremia.

Authors:  T D Mastro; J S Spika; P Lozano; J Appel; R R Facklam
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

10.  Bactericidal activity of ramoplanin against antibiotic-resistant enterococci.

Authors:  C C Johnson; S Taylor; P Pitsakis; P May; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191
  10 in total
  10 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

3.  Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation.

Authors:  Predrag Cudic; James K Kranz; Douglas C Behenna; Ryan G Kruger; Hellina Tadesse; A Joshua Wand; Yuri I Veklich; John W Weisel; Dewey G McCafferty
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

4.  Rapid detection of vancomycin-resistant enterococci.

Authors:  S C Edberg; C J Hardalo; C Kontnick; S Campbell
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

5.  Comparison of agar dilution, tube dilution, and broth microdilution susceptibility tests for determination of ramoplanin MICs.

Authors:  M T Kenny; M A Brackman
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

Review 6.  Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria.

Authors:  Nina Bionda; Jean-Philippe Pitteloud; Predrag Cudic
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

Review 7.  Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci.

Authors:  R Facklam; J A Elliott
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

8.  Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.

Authors:  N Mobarakai; J M Quale; D Landman
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.

Authors:  D M Citron; C V Merriam; K L Tyrrell; Y A Warren; H Fernandez; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 10.  Multidrug-resistant Enterococcus faecium. An untreatable nosocomial pathogen.

Authors:  R V Spera; B F Farber
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.